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Ovarian carcinoma is the commonest cause of death from gynaeco-
logical malignancy in most of the Western world. About 6000
women in the United Kingdom develop ovarian cancer each year and
about two-thirds of the women will die from the disease. The age-
standardised death rate of 15/100 000 has doubled in the past 70
years, and 5-year survival is just 30% (CRC CancerStats, 2000). 
Establishing the prognosis of a woman with ovarian cancer is an
important part of her evaluation and treatment. Multiple factors
such as age, grade, FIGO stage, residual disease, CA125, perfor-
mance status, the presence and absence of ascites, histology,
albumin, alkaline phosphatase, race and various molecular
markers (e.g. her-2/neu) have been reported as important prog-
nostic factors for women with the disease (Eisenhauer et al, 1999).
Attempts have been made to construct a prognostic index of these
factors (Van Houwelingen et al, 1989; Lund and Williamson,
1991; Ansell et al, 1993; Hogberg et al, 1993; Warwick et al, 1995;
Brinkhuis et al, 1996), but these efforts have been hampered by the
small size of available datasets. Large databases of ovarian cancer
patients are required to establish reliably the effects of different
prognostic factors on long-term outcome. 
In this paper we use data from over 1100 women to develop a prog-
nostic model for overall survival in ovarian cancer, assess its predic-
tive performance, and discuss its application in clinical practice. 
PATIENTS AND METHODS 
Study population 
Data from the Ovarian Cancer database of the ICRF Edinburgh
Medical Oncology Unit, established in 1984, were used. Data were
accrued from approximately 1400 ovarian cancer patients treated
at the Western General Hospital, Edinburgh. The subset of 1189
patients with primary epithelial ovarian carcinoma was used.
Patients were diagnosed between 01/01/1984 and 31/12/1999, and
follow-up data were available up until the end of December 2000.
For those patients lost to follow-up, vital status was checked in
February 2001. 
Outcomes of interest 
Overall survival, or equivalently time to death, was the outcome of
interest. Information about recurrence was not felt to be robust so
recurrence-free survival was not analysed. 
Prognostic factors 
The possibly relevant prognostic factors considered in the initial
stage of model-building process included age at diagnosis, FIGO
stage, grade of tumour (I = well differentiated, II = moderately
differentiated, III = poorly differentiated), histology, the presence
or absence of ascites, the diameter of the largest residual tumour
mass after primary cytoreductive surgery (< 2 cm, 2–5 cm and
> 5 cm), performance status using the ZUBROD-ECOG-WHO 
scale (0 = normal activity, 1 = symptoms, but nearly ambulatory, 
2 = some bed time, but needs to be in bed less than 50% of 
the normal daytime, 3 = needs to be in bed more than 50% of the
normal daytime and 4 = unable to get out of bed), and the first
CA125, alkaline phosphatase, and albumin laboratory test results
that fell between diagnosis and 7 days after the first chemotherapy.
As there was limited power to test for interactions, we proposed to
investigate, globally, for interaction effects between the following
prognostic factors: FIGO stage and log CA125 (Peters-Engl et al,
1999), FIGO stage and grade (Lund et al, 1990), FIGO stage and
histology (particularly mucinous–Lund et al, 1990), and grade and
histology (Carey et al, 1993). 
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Statistical methods 
Univariate analyses on continuous prognostic factors were
performed using Cox regression and categorical prognostic factors
were analysed using the Kaplan–Meier and the log-rank methods
(Hosmer and Lemeshow, 1999). The linearity (or more complex
forms) of the effect of continuous prognostic factors was assessed
using fractional polynomials (Royston and Altman, 1994). 
Because about half of the patients had at least one prognostic
factor missing, multiple imputation (Rubin, 1987) was applied to
account for missing prognostic factor data when considering all
variables at once. Our approach, assuming that these data are
missing at random (MAR) (Rubin, 1987), is similar to that
described by Van Buuren et al (1999). This involved creating 10
complete datasets by replacing missing values with simulated
values from a Gibbs sampling procedure (Gelfand and Smith,
1990). The analysis presented is a pooled summary of the results
from the 10 datasets. 
The fundamental method of multivariate analysis was Cox
regression. The models were formulated by systematically
removing predictors that were not significant (P > 0.05) starting
from a (full) model containing all the prognostic factors (including
factors that were non-significant in the univariate analysis). The
proportional hazard assumption for each predictor was tested
using an approximate score statistic of linear correlation between
the rank order of failure times in the sample and Schoenfeld partial
residuals (Grambsch and Therneau, 1994). 
We evaluated the predictive performance of models by consid-
ering measures of discrimination and calibration. Discrimination
refers to the ability to distinguish between high-risk and low-risk
patients, and was quantified using the c-index and Nagelkerke R2
(RN
2) (Harrell, 1999). The c-index – a generalisation of the area
under the Receiver Operating Characteristic (ROC) curve – is a
probability of concordance between predicted and observed
survival, with c = 0.5 for random predictions and c = 1 for a
perfectly discriminating model. Similarly, a RN
2 = 0 indicates no
predictive ability and RN
2 = 1 indicates perfect predictions.
Calibration (or reliability) refers to whether the predicted probabil-
ities agree with observed probabilities. Calibration was quantified
using an estimate of slope shrinkage (Harrell, 1999), based on 200
bootstrap samples, and a value of 1 indicates perfect calibration. 
All statistical analyses were carried out with S-Plus 2000
(Release 3) using the Hmisc, Design and MICE software 
libraries. The MICE library is available from www.multiple-
imputation.com. 
RESULTS 
Patient characteristics 
Patients were aged between 15 and 90 years at the time of diag-
nosis (median 61 years), presented at initial diagnosis with
predominantly FIGO stages III and IV (64.6%), and predomi-
nantly with a serous papillary (51.8%) histology. The potential
prognostic factors are summarised in Table 1. Performance status
levels 3 and 4 were combined because of small numbers. CA125
and alkaline phosphatase laboratory results were skewed, and a
summary of both transformed using natural logs is also presented.
The median times between diagnosis and the CA125, alkaline
phosphatase and albumin were 27 days (range 0–86 days), 30 days
(range 0–88 days) and 30 days (range 0–88 days), respectively. 
The treatment data are summarised in Table 2. 1140 (95.9%)
patients underwent surgery, and of those, 860 (75.4%) had
chemotherapy. Of the 893 (75.1%) patients who received
chemotherapy as part of first-line treatment, 656 (73.5%) patients
were treated with single-agent platinum regimens. The median
time between diagnosis and first course of chemotherapy was 32
days (range 1–115 days). 1080 (94.7%) patients were diagnosed at
time of surgery. Of those 49 (4.1%) patients who did not have
surgery, 42 were FIGO stage III or IV, and 7 were missing a FIGO
stage. Of those 296 (24.9%) patients who did not have
chemotherapy, 96 (32.4%) were FIGO stage III or IV, 159 (53.7%)
were FIGO stage I, and 10 were missing a FIGO stage. 
Long-term outcome 
Follow-up information was available on all 1189 patients. 842
(70.8%) patients had died at the time of censoring the data.
Median follow-up in the 347 (29.2%) patients who were living at
the point of censoring was 1665 days (range 29–5852 days). 5-
year survival in the cohort was 29.6% (95% Cl: 26.8–32.5%) in
keeping with international mortality rates. 
Univariate analysis 
Univariate analyses suggested that age, FIGO stage, the presence
or absence of ascites, performance status, histology, debulking,
albumin, grade, (log) CA125 and alkaline phosphatase were
significant (P ≤ 0.05) prognostic factors for overall survival.
Investigations of linearity of albumin, age, alkaline phosphatase
and CA125 in the univariate models suggested that alkaline phos-
phatase and CA125 required a natural log transformation. Missing
data were not included in these analyses. 
Missing data 
The frequency of missing values (labelled as ‘unknown’) for each
prognostic factor is presented in Table 1. Overall, there were 2045
(17.2%) missing values distributed in 831 (69.9%) patients. 236
(19.8%) patients had 4 or more missing values, and only 4 (0.4%)
patients with 7 or more missing prognostic factors. 1739 (85.0%)
of the missing cells resulted from missing information on albumin,
alkaline phosphatase, CA125 and performance status. The number
of patients contributing to a complete case analysis using all the
prognostic factors in Table 1 would be 358 (245 deaths), and
contributing to the final model (Table 3) would be 450 (323
deaths). The missing data methodology produced values for the
missing data that were consistent with the non-missing data,
compensated for the uncertainty of producing that data, and ulti-
mately has allowed us to perform an analysis with greater power
on all 1189 patients. 
Multivariate analysis 
Table 3 shows the results of the Cox regression analysis. There
was significantly greater risk of mortality associated with older
age, higher FIGO stage, poorer differentiated grade, the presence
of ascites, worse performance status, greater residual disease, a
lower albumin level and greater (log) alkaline phosphatase score.
We combined FIGO stages III and IV because their (log) hazard
ratios were identical to one decimal place (P = 0.66). Histology
comparisons – which used the serous group as a reference – were
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statistically non-significant, except comparisons of the
‘endometrioid’, ‘mixed mesodermal’, and ‘clear cell’ groups with
the ‘serous’ group (P ≤ 0.05). There were also differences between
the  ‘mixed mesodermal’ and ‘mucinous’ and ‘endometrioid’
groups (P < 0.05). Using a likelihood-ratio test, an overall
histology effect was significant (P < 0.0001), and therefore all
histological comparisons were included in the final model. The
only variable omitted was log CA125 which had a hazard ratio of
1.022 (95% Cl: 0.951–1.097) and was not statistically significant
(P = 0.54). There were no significant overall interaction effects
between FIGO stage and log CA125 (P = 0.32), FIGO stage and
grade (P = 0.74), and grade and histology (P = 0.06). Although,
there was no evidence of an overall FIGO stage and histology
interaction (P = 0.62), there was weak evidence (P = 0.03) that
those patients with a mucinous histology and advanced disease
have more aggressive disease and worse prognosis than those with
a serous histology (HR: 2.050; 95% CI: 1.073–3.916). 
A slope-shrinkage (= 0.948) close to 1 indicates there is little
need for recalibration and little evidence of over-fitting.
Reasonably large values for the c-index (= 0.786) and Nagelkerke
R2 (=0.511) indicate that the set of prognostic factors is explaining
the variation in outcome reasonably well, and this implies good
prediction for individual patients. Figure 1 illustrates good
discrimination ability for 4 risk groups constructed by partitioning
using the quartiles of the patients’ predicted risks based on the
model. The survival curves and 95% confidence intervals for the
risk groups are well separated. The c-index and Nagelkerke R2 in
those with early disease (FIGO stages I/II) was 0.715 and 0.250
respectively, whilst in advanced cases (FIGO stages III/IV), they
were 0.727 and 0.371, respectively. This demonstrates that the
model does discriminate well within groups with early or
advanced disease. 
Application of the model 
Our final prognostic model may be used to calculate expected
survival probabilities at various times for different patients. Figure 2
is a nomogram (Lubsen et al, 1978) which enables a clinician to
calculate a median survival time or 2-and 5-year survival probabili-
ties for patients. For each level of the prognostic factors there is a
Table 1 Potential prognostic factors 
n = 1189 
Prognostic variable N (%) Median (range)  P value 
Age at diagnosis (years) 1189 (100.0)  61 (15–90) <0.001 
FIGO stage <0.001 
I 281 (23.6)
II 119 (10.0)
III 590 (49.6)
IV 178 (15.0)
Unknown 21 (1.8)
Grade <0.001 
I 131 (11.0)
II 278 (23.4)
III 641 (53.9)
Unknown 139 (11.7)
Histology <0.001 
Serous papillary 616 (51.8)
Endometrioid 240 (20.2)
Mucinous 131 (11.0)
Mesonephroid (clear cell) 101 (8.5)
Mixed mesodermal 42 (3.5)
Adenocarcinoma 38 (3.2)
Undifferentiated 21 (1.8)
Ascites <0.001 
Presence 707 (59.5)
Absence 417 (35.1)
Unknown 65 (5.5)
Performance status (Zubrog) <0.001 
0 328 (27.6)
1 228 (19.2)
2 84 (7.1)
3+4 38 (3.2)
Unknown 511 (43.0)
Debulking <0.001 
Complete Debulk (<2cms) 641 (53.9) 
Partial Debulk (2–5 cms) 165 (13.9)
Non Debulk (>5cms) 302 (25.4)
Unknown 81 (6.8)
CA125 749 (63.0) 208 (6–22878) – 
Log CA125 749 (63.0)  5.3 (1.8–10.0) <0.001 
Alkaline phosphatase (ALP) 793 (66.7)  94 (26–1810) – 
Log ALP 793 (66.7) 4.5 (3.3–7.5) <0.001 
Albumin 797 (67.0) 39 (20–50) <0.001 
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number of points allocated, and the total number of points from all
prognostic factors can be converted into a median survival time or
predicted survival probabilities at 2 and 5 years. For example,
consider a 60-year-old woman (~36 points) with FIGO stage III
(~39 points), a grade II tumour (= 13 points), a serous papillary
histology (~8 points), no ascites present (= 0 points), a performance
status of level 1 (~7 points), residual disease less than 2 centimetres
(= 0 points), an albumin level of 30 (~14 points), and a log alkaline
phosphatase level of log 90 (= 4.50) (~30 points). This patient has a
total score of approximately 147, which translates into survival
probabilities at 2 and 5 years respectively of approximately 0.7 and
0.25. The median survival time is approximately 2.5 years. 
DISCUSSION 
Despite the plethora of published prognostic models in cancer,
very few are used routinely in clinical practice (Wyatt and Altman,
1995). One problem associated with the acceptance of these
models relates to their construction, which predominantly relies on
small data sets. Sometimes limited analysable data are a result of
low prevalence of disease and/or missing data. When performing a
retrospective evaluation of large clinical databases, missing data
can be problem. It is usual to exclude from an analysis those indi-
viduals on whom data are missing, and this practice leads to a
reduction in the statistical power of an analysis and also leads to
invalid results if the excluded group is a selective sub-sample of
the entire dataset with respect to prognosis. 
We applied a missing data methodology (multiple imputation)
and Cox regression to construct a prognostic model for overall
survival in 1189 ovarian cancer patients. This model included age,
FIGO stage, ascites, performance status (2, 3 and 4 versus 0),
grade, histology (particularly ‘mixed mesodermal’ versus other
types), albumin, (log) alkaline phosphatase and debulking as
(significant) prognostic factors (P ≤ 0.05). Measures of predictive
performance indicated that this model is well calibrated (i.e. has
good ability to produce unbiased estimates of outcome), and has
good discrimination abilities (i.e. has the ability to provide reason-
ably accurate predictions for individual patients). We also produced
a nomogram for our model, which enables calculation of median
survival times and expected survival probabilities for individual
patients at 2 and 5 years. 
Could the model be used in clinical practice? To help answer
this question we have addressed 3 issues. First, we have reviewed
previously published models – specifically the composition of
models, sample size of studies used to construct the models, and
ultimately their predictive ability. Second, we consider the gener-
alisability and transportability of the model to other populations of
ovarian cancer patients. Third, we comment on the practicability
of applying the current model in a clinical setting. 
Existing models 
We found many reports of multivariate models, but there are prob-
lems in synthesising this information into a meaningful overview.
These problems include: small sample size of studies, limited
details regarding which factors were considered in the analysis,
inconsistencies in methodology between studies evaluating the
same factor (e.g. categorisation of continuous factors or handling
missing data), and non-uniform patient populations both between
and within studies. The latter can be minimised when the data are
from a prospective trial. Those analyses that are retrospective are
often flawed, first, by considering response to treatment as a
potential prognostic factor and, second, by not accounting for the
use of different chemotherapy regimens. 
We have restricted our review of prognostic models to those
published since 1985 and with more than 200 patients in the study.
This can be justified by potential problems with changes in treat-
ment practice and small sample sizes. We have focused on vari-
ables that were available for analysis and their statistical
significance in the model. There was no consideration of a vari-
able’s form or the magnitude of its hazard ratio(s). Table 4 is a
summary of our results. The above limitations ignored, the most
consistent  ‘statistically significant’ prognostic factors are stage
and post-operative residual disease. Histology and grade were
incorporated into most assessments, but were less often signifi-
cant. Some studies included either early or advanced ovarian
cancer, while others included both groups. Although treatment
practices may differ between early or advanced stage groups, it
Table 2 Treatment 
n = 1189 
N or (median) % or (range) 
Surgery 1140 95.9 
Time from diagnosis to Surgery (days) (0)  (0–56) 
Chemotherapy 893 75.1 
Single agents
Cisplatinum 258 28.9 
Carboplatin 246 27.5 
Chlorambucil 135 15.1 
Other 17 1.9 
Platinum-based combination
Cisplatinum / prednimustine 83 9.3 
Platinum / taxane combinations 38 4.3 
Cisplatinum / alpha interferon 29 3.2 
Cisplatinum / topotecan 28 3.1 
Carboplatin / hexalen 27 3.0 
Cisplatinum / 5FU / hexamethylmelamine /  19  2.1 
prednisolone
Other 11 1.2 
Non-platinum combinations 2 0.2 
Time from diagnosis to chemotherapy (days) (32)  (1–115) 
Surgery and chemotherapy 860 72.3 
Figure 1 Survival of risk groups. Based on the following cut-points of the
linear predictions from the Cox model: –0.9922, 0.1105, and 0.9073 
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seems sensible to use all FIGO stages together in a dataset 
(if possible) because, given a larger magnitude of patients, 
multivariate analyses can detect heterogeneity in prognostic 
factor effects between the various stages by fitting interaction-
terms. 
In those studies (Swenerton et al, 1985; Hogberg et al, 1993;
Hartmann et al, 1994; Kehoe et al, 1994; Kosary, 1994; Meden 
et al, 1995; Marx et al, 1997; Brun et al, 2000) that considered a
complete (stage) case mix, grade and FIGO stage were consis-
tently significant, with residual disease, histology, performance
status, ascites, and albumin being significant in some, but not all
models. The largest study (Kosary, 1994) used National Cancer
Institute’s Surveillance, Epidemiology, and End Results (SEER)
data on 21 240 patients diagnosed between 1973 and 1987.
Although, there was substantial power, data on residual disease
and performance status were not presented. Among other large
studies, Kehoe et al (1994) presented a study of 1184, but by
removing patients with any missing data – an approach that could
bias their results – the multivariate model was based on just 451
(38%) patients. Swenerton et al (1985) developed a model based
on 556 patients with all FIGO stages, but their patients were
treated with pre-platinum-based regimens. 
Brun et al (2000) included a chemotherapy factor in their multi-
variate model as a way of adjusting for those patients with
different chemotherapy regimens, and comparing those who
received and did not receive chemotherapy. Although there was a
statistically significant difference between those who received and
did not receive chemotherapy, there was homogeneity between the
effects of different chemotherapy regimens. In our multivariate
model, the addition of a chemotherapy factor (applied versus not
applied) was statistically significant (P = 0.02). This is not unex-
pected as treatment decisions are based on baseline prognostic
factors. For example, women with early stage disease are less
likely to receive chemotherapy. This is confirmed in our cohort
with the proportion of those treated with chemotherapy in FIGO
stages I, II and III/IV being 43%, 74% and 88% respectively. We
also considered the effects of different chemotherapy regimens in
the modelling framework above, and found there was no differ-
ence in overall survival between single platinum and combination
regimens (P = 0.92). Although these are not randomised compar-
isons and interpretation is problematic, this result may be due to
the high proportion (83%) of those chemotherapy patients
receiving any form of platinum-based therapy, and the effect of
less follow-up in the combination group (median 1.8 years). Fewer
Table 3 Multivariate prognostic model 
n = 1189, No. deaths = 842 
Prognostic factors HR (95% Cl) P value 
Age (years) 1.020 (1.012, 1.028)  <0.001 
FIGO stage
I 1.000
II 1.807 (1.299,2.514) <0.001 
II+IV 3.029 (2.299,3.991)  <0.001 
Grade
I 1.000
II 1.487 (1.070,2.067) 0.017 
III 1.560 (1.126,2.160) 0.004 
Histology
Serous Papillary 1.000
Endometrioid 0.811 (0.657, 1.000) 0.050 
Mucinous 0.951 (0.697, 1.297) 0.749 
Clear Cell 1.381 (1.055, 1.807) 0.019 
Mixed Mesodermal 2.007 (1.392, 2.894) <0.001 
Adenocarcinoma 1.265 (0.833, 1.920) 0.269 
Undifferentiated 1.537 (0.941, 2.511) 0.086 
Ascites
Absence 1.000
Presence 1.390 (1.171, 1.650) <0.001 
Perf. Status
0 1.000
1 1.123 (0.897, 1.406) 0.306 
2 1.418 (1.072, 1.875) 0.015 
3+4 3.390 (2.231, 5.151) <0.001 
Debulking
<2 cms 1.000
2–5 cms 1.749 (1.398,2.189)  <0.001 
>5 cms 1.836 (1.500, 2.248)  <0.001 
Log Alkaline Phosp. 1.548 (1.301, 1.840)  <0.001 
Albumin 0.979 (0.960, 0.999) 0.036 
Model performance Slope = 0.948 c-index =
0.786 RN
2 = 0.511 
HR = hazard ratio, RN
2 = Nagelkerke R2. 
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than 5% of chemotherapy patients received new first-line regi-
mens, such as taxanes, and in the future our model may have to
account for the potential survival improvement from these and
other therapeutic advances. 
Given that 65% of our cohort were FIGO stage III or IV, it
seems reasonable to compare our model with those from studies of
advanced ovarian cancer. Our dataset (n = 768) is one of the
largest studies when considering these cases alone. A larger study,
Marsoni et al, (1990), combined data from 4 clinical trials on
FIGO stage III and IV patients. This study of 914 patients
produced a model including age, FIGO stage, histology and
residual disease. However, it was found that performance status
could replace age and residual disease in those 721 patients not
missing performance status. Of those other studies with more than
200 advanced cases (Marsoni et al, 1990; Alberts et al, 1993;
Bruzzone et al 1995; Peters-Engl et al, 1999), the maximum size
was 512 cases, and stage and residual disease were the core
factors, with grade, histology, performance status, ascites, and
albumin being in some, but not all models. We have not found a
statistically significant difference between FIGO stages III and IV.
Once again, there are studies with multivariate analyses performed
using substantially fewer patients than those initially recruited to
the study. Some studies (Van Houwelingen et al, 1989; Lund and
Williamson, 1991; Kosary, 1994; Nagele et al, 1995; Peters-Engl
et al, 1999; Brun et al, 2000) have dealt with missing data for each
factor by including it as a separate level or category. This practice
can lead to unrealistic hazard ratios and underestimation of stan-
dard errors (Greenland and Finkle 1995), but may be better than
excluding whole cases. 
CA125 was not significant in our model, and it is now widely
accepted that baseline measurements do not predict long-term
survival of patients, especially in patients with advanced ovarian
cancer (Peters-Engl et al, 1999). There are some prognostic factors
from Table 4 that are not present in our model. These include race,
type of surgeon, and new molecular markers. Decreased survival
has occasionally been observed in non-white women, and it is
unknown whether this is due to racial differences in stage distribu-
tion, histology or grade or if there are possible questions
concerning treatment differences, access to care or other socio-
economic factors. Race has been an important prognostic factor in
Points
Age
FIGO
Grade
Histology
Ascites
Perf.stat
Debulking
Log.ALP
Albumin
Total Points
2 yr survival prob.
5 yr survival prob.
Median Survival Time (years)
0
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2
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0.95 0.9 0.8 0.70.6 0.5 0.4 0.3 0.2 0.1
0.9 0.8 0.70.6 0.5 0.4 0.3 0.2 0.1
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Figure 2 Nomogram for median, 2 and 5 year survival. Aden = Adenocarcinoma, CC = Clear Cell, End = Endometrioid, Und = Undifferentiated, Perf.stat =
Performance status, Log.ALP = log Alkaline Phosphatase
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Table 4 Selected multivariate prognostic models for overall survival in primary ovarian cancer with >200 patients in the study dataset and published since 1985 
Reference No.  No. in Diagnosis  Stage  Rx FIGO Grade Histology Residuum Age  Ascites Performance  CA125 Albumin  Alkaline  Other  
patients final year included stage status phosphat. significant
model (19XX) factors
1 556 <521 66–76 All C  ** – * –– *
6 332 223 84–87 All P ** – **
7 284 284 76–90 All M ** – *
8 1184 451 85–87 All M ** – ** – Surgeon 
9 21240 21240 73–87 All ?  ** * ** Race, 
Node 
status 
12 266 266 82–92 All ? ** –– * Her-2 
15 251 251 82–92 All ? ** –– * Her-2 
17 287 287 75–95 All M * – ** – Chemo 
13 201 201 84–93 I C,P * –– *
2 268 268 79–83 II–IV CP  v ** – * – ** Hospital 
CHAP
4 301 301 81–86 II–IV CHAP – ** * –– ** No. Metas 
10 512 512 82–94 II–IV P  – * – * – *
14 362 213 81–91 II–IV P  –– – * – **
11 455 <435 83–91 III M  ** * * **
3 914 852 78–86 III–IV P * – ** * [*] 
5 342 291 85–89 III–IV  C v P ** * Race 
16 210 210 84–96 III–IV P – * – ** ––
This 1189 1189 84–99 All M ** * * ** * – **
Study
*Statistically significant (P ≤ 0.05), –not statistically significant, Rx chemotherapy regimen, ? data not presented, [*] if performance status included, age and residual disease omitted, P = Platinum based regimens, 
CP = cyclophosphamide and cisplatin, M = Mixed platinum and non-platinum regimens, C = cyclophosphamide, CHAP = cyclophosphamide, doxorubicin, hexamethylmelamine, cisplatin, 1 = Swenerton (1985), 
2 = Van Houwelingen (1989), 3 = Marsoni (1990), 4 = Lund (1991), 5 = Alberts (1993), 6 = Hogberg (1993), 7 = Hartmann (1994), 8 = Kehoe (1994), 9 = Kosary (1994), 10 = Bruzzone (1995), 11 = Makar (1995), 
12 = Meden (1995), 13 = Nagele (1995), 14 = Warwick (1995), 15 = Marx (1997), 16 = Peters-Engl (1999), 17 = Brun (2000). 
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studies from the USA, but is less relevant in our homogenous
‘Caucasian’ Edinburgh cohort. Several studies have found that a
trained gynaecologist and not a general surgeon should manage
the surgery of a patient (Junor et al., 1999). This is not a concern in
our dataset as more than 90% of the Edinburgh patients have been
operated on by a gynaecologist. In the past few years there have
been several reports about the prognostic impact of molecular
markers, including oncogene products (her-2/neu, p21), tumour
supressor gene products (p53, p16, pRB) and measures of drug
sensitivity (Pgp, LRP, MRP, GST, BAX). There is difficulty in
distilling these data into a clear conclusion on which of these
measures are important prognostic factors, since there are few
reports of substantial size. Two studies presented include her-
2/neu, but we do not have sufficient data to test this factor.
Although it is foreseeable that computer chip technology may
produce new (molecular and genetic) prognostic factors and the
prognostic models for the future are likely to be completely
different, currently there is not enough data or follow-up to rigor-
ously test them. The best way to do this is by large prospective
studies, randomised if possible (Simon and Altman, 1994). 
None of the studies in Table 4 formally assessed predictive
ability using the calibration and discrimination measures we
applied. Factors that affect predictive ability include: sample size,
number of events, quality of the study design, quality of the data,
and efficient model construction. Due to our sophisticated manage-
ment of missing values, the model compares favourably to other
studies with respect to sample size, number of deaths and power.
Development of prognostic models is an exploratory analysis. By
searching among many variables, there is a risk of including some
variables that are not truly prognostic (Simon and Altman, 1994).
During the construction of the model, we minimised false positive
errors by assessing a limited number of predetermined variables.
We also assessed assumptions associated with the multivariate
Cox model, including the linearity of continuous variables and
proportionality, and these were satisfied. 
Some studies (Swenerton et al, 1985; Van Houwelinger et al,
1989; Lund et al, 1990; Marsoni et al, 1990; Lund and Williamson
et al, 1991; Hogberg et al, 1993; Kappen and Neijt, 1993; Warwick
et al, 1995) assessed discrimination by creating risk groups (via
indices) based on the same methodology we employed. Log-rank
methodology was applied to assess differences in these groups. As
the construction of the risk groups is arbitrary, it is too difficult to
compare them using measures of separation. 
Transportability to other populations 
The Edinburgh population is predominantly Caucasian and, given
the discussion of race above, our model may not be suitable
outside this type of population. To assess the transportability of
our model requires validation in at least one independent popula-
tion (Altman and Royston, 2000). Table 4 shows that the variables
in our model are broadly consistent with most of the other
published models. In future work we plan to externally validate
our model and a possible index. To our knowledge, 2 groups (Lund
et al, 1990; Carey et al, 1993) have attempted to externally vali-
date a model or index. Lund et al (1990) used Danish trial data to
validate a statistical model from Dutch trial patients containing
FIGO stage, grade, performance status, ascites, and residual
disease. They found that performance status and residual disease
were the only factors in common, and suggested that these factors
would be a starting point for a basic index. Carey et al (1993)
presented a larger validation of models from Dembo et al (1982),
but their outcome of interest was ovarian cancer mortality. Overall
survival is a more reliable outcome. 
Practicability of applying a model in a clinic 
We have shown how a nomogram may be used to assess a
woman’s prognosis, and could potentially be used as the basis for
making treatment decisions. However, any predictions would need
to be presented with a measure of uncertainty, perhaps in the form
of confidence limits. Our model, if and when validated, could
benefit from being simplified and converted to a web-based
medium for clinical utility. 
In summary, we have constructed a prognostic model that is
based on one of the largest analysable datasets in ovarian cancer.
Our model is broadly consistent with other models in the literature,
but it needs to be validated in an external dataset. In coming years
the identification of prognostic molecular factors may change such
models considerably. The production of valid models in the future
will depend on the availability of large databases where both stan-
dard factors and molecular markers can be assessed. This could be
done in the context of large (randomised) multicentre trials where
treatment, follow-up and endpoints are predefined and measured
according to identical criteria in all patients and, ideally, multiple
laboratory measures are incorporated. We believe our model is one
of the best available until such evidence is accumulated. 
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